Neural stem cell-mediated cancer treatment
Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation. The method entails administrating to a subject a pharmaceutical composition comprising a combination of NSCs and an oncolytic virus, and/or NSCs packaged with one or more immunomodulatory viruses expressing one or more immunity checkpoint inhibitors, including adaptive immunity checkpoint inhibitors and innate immunity checkpoint inhibitors. The immunity checkpoint inhibitors include shRNAs against the immunity checkpoint proteins. The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.
1. A method of treating cancer comprising administrating to a subject a therapeutically effective amount of neural stem cells (NSCs) and an oncolytic adenovirus, and administering a therapeutically effective amount of a PD-L1 inhibitor to the subject, before, during, or after administration of the neural stem cells and the oncolytic adenovirus, wherein the ratio of NSCs to the oncolytic adenovirus is about 100:1, about 200:1, about 300:1, about 400:1, about 500:1, about 600:1, about 700:1, about 800:1, about 900:1, about 1000:1, about 1100:1, about 1200:1, about 1300:1, about 1400:1, about 1500:1, about 1600:1, about 1700:1, about 1800:1, about 1900:1, or about 2000:1.
2. The method of claim 1 , wherein the neural stem cells and the oncolytic adenovirus are administered simultaneously or sequentially.
3. The method of claim 1 , wherein the neural stem cells and the oncolytic adenovirus are administered every day, every other day, every three days, every four days, every five days, every six days, weekly, every 10 days, bi-weekly, or monthly.
4. The method of claim 1 , wherein the neural stem cells and the oncolytic adenovirus are administered over the period of about one week, about two weeks, about three weeks, about four weeks, about five weeks, about six weeks, about seven weeks, about eight weeks, about nine weeks, about ten weeks, about twelve weeks, about four months, about five months, about six months, about seven months, about eight months, about nine months, about ten months, about eleven months or about twelve months.
5. The method of claim 1 , the neural stem cells and the oncolytic adenovirus are administered by intraperitoneal injection.
6. The method of claim 1 , wherein the PD-L1 inhibitor is a PD-L1 antibody or an shRNA against PD-L1 to the subject.
7. The method of claim 1 , further comprising administering a therapeutically effective amount of a chemotherapeutical agent for treating the cancer to the subject, before, during, or after administration of the neural stem cells and the oncolytic adenovirus.
8. The method of claim 7 , wherein the chemotherapeutic agent is cisplatin, and the cancer is ovarian cancer.
9. The method of claim 1 , wherein the oncolytic adenovirus is AR2011.
10. The method of claim 1 , wherein the oncolytic adenovirus is CRAd-Survivin-pk7, CRAd-SPARC-pk7, or CRAd-SPARC-pk3/5.
11. The method of claim 1 , wherein the cancer is selected from the group consisting of peritoneal cancer, ovarian cancer, bladder cancer, pancreatic cancer, colorectal cancer, gastric cancer, brain cancer, and liver cancer.
12. The method of claim 1 , wherein the cancer is a metastatic cancer.
13. A pharmaceutical composition comprising a therapeutically effective amount of neural stem cells (NSCs) and an oncolytic adenovirus, and a therapeutically effective amount of a PD-L1 inhibitor, wherein the ratio of NSCs to the oncolytic adenovirus is about 100:1, about 200:1, about 300:1, about 400:1, about 500:1, about 600:1, about 700:1, about 800:1, about 900:1, about 1000:1, about 1100:1, about 1200:1, about 1300:1, about 1400:1, about 1500:1, about 1600:1, about 1700:1, about 1800:1, about 1900:1, or about 2000:1.
14. The pharmaceutical composition of claim 13 , wherein the neural stem cells are transduced with the oncolytic adenovirus.
15. The pharmaceutical composition of claim 13 , wherein the PD-L1 inhibitor is a PD-L1 antibody or an shRNA against PD-L1.
16. The method of claim 1 , wherein the cancer is ovarian cancer.